New, more contagious coronavirus variants from Britain, South Africa, and Brazil are raising alarms. Academic experts share why better masking and faster vaccination offer the best chance to avoid another deadly surge.
All viruses mutate. SARS-CoV-2, the virus at the root of the COVID-19 pandemic, has mutated in a variety of ways since it first began spreading in humans in 2019, but few of these mutations have changed the virus enough to alter its impact on people — at least until late 2020.
In the past few months, several variants — which arise from mutations in the virus’s genetic makeup — have caused concern in the international scientific community. Among those are B.1.1.7, a strain that is driving a surge of hospitalizations and deaths in the United Kingdom; B.1.351, which was first detected in South Africa; and P.1, which is now surging in Brazil. Just last week, researchers announced the discovery of a homegrown strain in California, labeled B.1.426 or CAL.20C, which they believe could have contributed to the alarming spike in the state, according to the Los Angeles Times.
What does this mean as a weary world enters the second year of the pandemic? AAMCNews spoke with Ashish Jha, MD, MPH, dean of the Brown University School of Public Health, and Gigi Gronvall, PhD, a senior scholar at the Johns Hopkins Center for Health Security, who offered their expertise about what we know — and don’t know — about the new variants.
Are the new variants more contagious?
Jha says that evidence suggests the variants from the United Kingdom, South Africa, and Brazil are about 50% more contagious than the strain common in the United States. Scientists are still studying the transmissibility of the California variant, but they believe it is also more contagious. All the variants have mutations to the spike protein that the virus uses to gain entry to and infect human cells.
“That’s really problematic,” Jha says.
Do they cause more severe disease?
British officials said last week that there is some preliminary evidence that the U.K. variant is deadlier, but researchers cautioned that the data were still limited.
“We need to assume now that what has been circulating dominantly in the U.K. does have a certain degree of increase in what we call virulence, namely the power of the virus to cause more damage, including death,” Anthony Fauci, MD, the nation’s top infectious disease expert and chief medical advisor to the president, said Sunday on “Face the Nation.”
Even if people generally don’t get sicker because of the new strains, larger outbreaks can still result in a higher death toll. The more people become infected, the more people will become seriously ill, further straining health systems that are already taxed from COVID-19.
Will the vaccines still be effective against the new variants?
So far, the data suggest that the vaccines will still produce immunity against the new variants.
Laboratory studies have shown the Pfizer-BioNTech vaccine to be just as effective on the strain prevalent in the United Kingdom. And Moderna, the company that manufactures the other vaccine currently approved in the United States, said on Monday that its studies show its vaccine is effective against both the U.K. and South Africa variants — although, in relative terms, it is less effective against the South Africa variant. The company is working on developing a booster shot to better guard against this variant.
Jha says his fear is that if the coronavirus continues to spread at the rate it is currently spreading, then other variants that can further evade the vaccine will develop.
The best way to prevent that from happening — and to save the United States from being crushed by another surge when the more contagious variants spread more widely — is to get vaccines in as many arms as possible.
Fauci reiterated at the White House briefing last Thursday that, even if the vaccines aren’t as effective on the new variants, they will still be helpful. He added that the vaccine can be altered to address changes in the virus if necessary.
Can people with antibodies from a previous COVID-19 infection be reinfected by the new variants?
Experts aren’t sure if a previous COVID-19 infection will protect against the new variants. One study from South Africa suggests that the variant there could evade antibodies from the more common COVID-19 strain. This issue could also make one promising therapy — the use of plasma from people who have been previously infected to boost a sick person’s immune response — ineffective.
But Jha says that scientists will need more clinical data to determine whether antibodies are truly ineffective in the new variants.
“We don’t know enough yet to worry,” he says.
Do the new variants impact children differently?
While there was initially some worry that children might be more severely impacted by the new variants, Gronvall says the latest data suggest this is not the case.
What does the emergence of new variants mean for the academic medicine community?
Gronvall notes that it’s critical to make sure our communities are getting vaccinated and practicing precautions to prevent the spread — or else already stressed health systems will be hit hard once again.
“It’s not a good news story,” she says.
Jha hopes to see leaders at academic medical institutions being voices of clarity in their communities.
“They have a really important role to play in their communities in helping people over the next few months,” he says. The message must be, “Double down on public health measures. You don’t have to do this forever, it’s just a few more months.”